Congenital aniridia - A comprehensive review of clinical features and therapeutic approaches.

Aniridia Cataract Complications Dry eye disease Foveal hypoplasia Genetics Glaucoma Keratopathy Systemic findings Treatment

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
Historique:
received: 18 06 2020
revised: 16 02 2021
accepted: 23 02 2021
pubmed: 7 3 2021
medline: 31 3 2022
entrez: 6 3 2021
Statut: ppublish

Résumé

Congenital aniridia is a rare genetic eye disorder with total or partial absence of the iris from birth. In most cases the genetic origin of aniridia is a mutation in the PAX6 gene, leading to involvement of most eye structures. Hypoplasia of the fovea is usually present and is associated with reduced visual acuity and nystagmus. Aniridia-associated keratopathy, glaucoma, and cataract are serious and progressive complications that can further reduce visual function. Treatment of the ocular complications of aniridia is challenging and has a high risk of side effects. New approaches such as stem cell therapy may, however, offer better prognoses. We describe the various ocular manifestations of aniridia, with a special focus on conditions that commonly require treatment. We also review the growing literature reporting systemic manifestations of the disease.

Identifiants

pubmed: 33675823
pii: S0039-6257(21)00065-5
doi: 10.1016/j.survophthal.2021.02.011
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1031-1050

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Erlend C S Landsend (ECS)

Department of Ophthalmology, Oslo University Hospital, Oslo, Norway. Electronic address: elandsend@gmail.com.

Neil Lagali (N)

Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Tor P Utheim (TP)

Department of Ophthalmology, Oslo University Hospital, Oslo, Norway; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH